Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that weekly azathioprine pulse therapy was more effective than betamethasone oral mini-pulse in promoting hair regrowth in patients with moderate to severe alopecia areata.

This study observed that, after 90 hours of light exposure, Finasteride retained 57% of its concentration, whereas Diclofenac and Naproxen retained only 12% and 9%, respectively.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study found that topical cetirizine increased hair shaft thickness and improved clinical outcomes from the patients' perspective in female androgenetic alopecia compared to minoxidil alone, with similar side effect profiles.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study reported that a solid lipid nanoparticle-based gel formulation, specifically optimized for psoriasis, improved drug loading capacity and release properties using high-pressure homogenization, suggesting its potential efficacy as a topical treatment.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

Clascoterone safely promotes hair growth similar to minoxidil.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this study, patients with frontal fibrosing alopecia showed more actinic damage than control subjects, suggesting sunscreen use by these patients may be a consequence rather than a cause of the condition.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

In this double-blind randomized controlled trial, both rosemary extract lotion and 2% ketoconazole lotion were effective for treating scalp seborrheic dermatitis, but rosemary lotion reduced itching more significantly, while ketoconazole was more effective in reducing dandruff.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

The treatment slightly increased hair growth and was safe for most women.

This case report describes a patient with various conditions, including ulcerative colitis and azathioprine-induced liver injury, and reviews related literature on these coexisting conditions.

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study found that sinapic acid demonstrated antioxidant and anti-inflammatory effects against UVB-induced damage in human keratinocytes, suggesting its potential as an anti-aging cosmetic ingredient.

This systematic review reported that while combining low-dose oral minoxidil with Janus kinase inhibitors may enhance treatment outcomes in alopecia areata, the evidence remains weak due to limited sample sizes and potential publication bias, and more rigorous trials are necessary to assess efficacy and safety.